Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 2010 results found since Jan 2013.
Knowledge and Attitudes Concerning Herpes Zoster among People with COPD: An Interventional Survey Study
Vaccines (Basel). 2022 Mar 10;10(3):420. doi: 10.3390/vaccines10030420.ABSTRACTHerpes zoster (HZ) is common in older adults with conditions such as chronic obstructive pulmonary disease (COPD). Effective prevention is available through vaccination, but HZ vaccine uptake remains incomplete. Using an online survey of people with self-reported COPD, ShiPPS assessed HZ risk awareness, HZ vaccine use and barriers, and the impact of an HZ educational video on vaccine intent. USA members of the COPD Foundation's Patient-Powered Research Network aged >50 years were surveyed in fall 2020. The responses were analyzed using de...
Source: Herpes - March 26, 2022 Category: Infectious Diseases Authors: Barbara P Yawn Debora D Merrill Sergio Martinez Elisabeth Callen Janice Cotton Dennis Williams Natalia Y Loskutova Source Type: research
Strategies to improve vaccination rates in people who are homeless: A systematic review
Vaccine. 2022 Apr 25:S0264-410X(22)00436-4. doi: 10.1016/j.vaccine.2022.04.022. Online ahead of print.ABSTRACTPeople who are homeless experience higher rates of vaccine-preventable disease, including COVID-19, than the general population, and poorer associated health outcomes. However, delivering vaccinations to people who are homeless is complex, and there is a lack of evidence to inform practice in this area. The aim of this systematic review is to: (a) identify, (b) analyse the characteristics of, and (c) evaluate the outcomes of, strategies to improve vaccination rates in people who are homeless. Literature was retriev...
Source: Vaccine - April 28, 2022 Category: Allergy & Immunology Authors: Laura K McCosker Asmaa El-Heneidy Holly Seale Robert S Ware Martin J Downes Source Type: research
General practitioner knowledge gaps regarding live attenuated zoster vaccination of immunocompromised individuals: An ongoing concern?
DISCUSSION: While most GPs surveyed had good knowledge, notable gaps were identified. Further efforts are needed to promote awareness of recommendations, particularly for immunocompromised individuals. The availability of Shingrix, a non-live recombinant subunit zoster vaccine, in the private market provides an alternative, especially for immuncompromised patients.PMID:35773163 | DOI:10.31128/AJGP-09-21-6175
Source: Herpes - June 30, 2022 Category: Infectious Diseases Authors: Ramesh Manocha Kristine Macartney Frank Beard Aditi Dey Harunor Rashid Ketaki Sharma Anastasia Phillips Jean Li-Kim-Moy Source Type: research
Association of asthma and herpes zoster, the role of vaccination: A literature review
Immun Inflamm Dis. 2022 Nov;10(11):e718. doi: 10.1002/iid3.718.ABSTRACTHerpes Zoster (HZ) is the reactivation of a previous infection with varicella-zoster virus (VZV) which shares the same mode of transmission as HZ. It presents with painful erythematous vesicles in a dermatome which is characterized by a burning sensation before and after the rash. Any conditions with suppressed cellular immunity example diabetes mellitus, chronic obstructive pulmonary disease, asthma, cardiovascular diseases, chronic steroid uses, malignancy, etc. causes reactivation of the virus. Impaired immune responses in asthma patients either in a...
Source: Herpes - October 27, 2022 Category: Infectious Diseases Authors: Abhigan Babu Shrestha Tungki Pratama Umar Yasmine Adel Mohammed Manjil Aryal Sajina Shrestha Unnat Hamal Sapkota Lukash Adhikari Shumneva Shrestha Source Type: research
Disseminated varicella zoster virus infection following live attenuated herpes zoster vaccine: descriptive analysis of reports to Australia's spontaneous vaccine pharmacovigilance system, 2016-2020
CONCLUSIONS: Disseminated VZV is potentially life-threatening and occurs mostly in those with severe immunocompromise. Inadvertent administration of ZVL to immunocompromised individuals has occurred despite initial provider guidance and education. Multiple additional strategies to assist providers to identify contraindications have been implemented to prevent adverse outcomes.PMID:36707120 | DOI:10.1136/bmjopen-2022-067287
Source: Herpes - January 27, 2023 Category: Infectious Diseases Authors: Jean Li-Kim-Moy Anastasia Phillips Adelaide Morgan Catherine Glover Sanjay Jayasinghe Brynley P Hull Aditi Dey Frank H Beard Megan Hickie Kristine Macartney Source Type: research
Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases
CONCLUSIONS: The frequencies of vaccinations against influenza, Streptococcus pneumoniae and HZ have increased during recent years. While this can be partly explained by continuous efforts in patient education during the outpatient visits, the COVID-19 pandemic might also have contributed. Nevertheless, the persistently high incidence and mortality of these preventable diseases in patients with AIIRDs mandates further efforts to increase vaccination coverage, particularly in SLE patients.PMID:37112672 | DOI:10.3390/vaccines11040760
Source: Herpes - April 28, 2023 Category: Infectious Diseases Authors: Marco Krasselt Ulf Wagner Olga Seifert Source Type: research
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
CONCLUSIONS: These findings highlight the high economic burden of HZ among individuals with RA in the United States. Strategies to reduce the risk of HZ in patients with RA (such as vaccination) may serve to reduce this burden. Video abstract.PMID:37219822 | DOI:10.1007/s40744-023-00549-x
Source: Herpes - May 23, 2023 Category: Infectious Diseases Authors: David Singer Philippe Thompson-Leduc Sara Poston Deepshekhar Gupta Wendy Y Cheng Siyu Ma Francesca Devine Alexandra Enrique Mei Sheng Duh Jeffrey R Curtis Source Type: research
Use of Information and Communication Technology Strategies to Increase Vaccination Coverage in Older Adults: A Systematic Review
CONCLUSIONS: Prevention programs using ICT tools could be effective in promoting immunizations among older adults.PMID:37515089 | DOI:10.3390/vaccines11071274
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Alessandra Buja Giulia Grotto Mustapha Taha Silvia Cocchio Vincenzo Baldo Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Vaccination in rheumatic disease patients: results of a pilot quality improvement program
CONCLUSIONS: The implementation of a pilot vaccination QI program led by rheumatology fellows-in-training showed promising preliminary benefits in the vaccination uptake among RD patients and helps to evaluate the barriers to surpass.PMID:35079179 | PMC:PMC8768043 | DOI:10.5114/reum.2021.112349
Source: Herpes - January 26, 2022 Category: Infectious Diseases Authors: Gabriel Figueroa-Parra Andrea Moreno-Salinas Leticia Santoyo-Fexas Carmen Magdalena Gamboa-Alonso Juan Pablo Carrizales-Luna Ivan de Jesus Hernandez-Galarza Dionicio Angel Galarza-Delgado Jorge Antonio Esquivel-Valerio Source Type: research
Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report
We describe the case of VZV meningitis post BNT162b2 mRNA vaccination in a young immunocompetent patient. A 39-year-old patient with no medical history presented with a vesicular rash, headache, nausea and fever, days after receiving BNT162b2 mRNA vaccination. CSF analysis revealed a pleocytosis, and VZV DNA was confirmed by PCR testing. The patient received intravenous aciclovir with resolution of symptoms within 48 h. He was discharged after 14 days of treatment. Case reports of herpes zoster reactivation post vaccination and details of subsequent successful vaccination course completion have allowed us to recommend the ...
Source: Herpes - February 21, 2022 Category: Infectious Diseases Authors: Colm Kerr Susan O'Neill Anna Szucs Oliver Darmody Claire Williamson Ciaran Bannan Concepta Merry Source Type: research
COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study
Lancet Reg Health Eur. 2022 May 29;18:100410. doi: 10.1016/j.lanepe.2022.100410. eCollection 2022 Jul.ABSTRACTBACKGROUND: Pregnant individuals with coronavirus disease 2019 (COVID-19) are at increased risk of severe disease, prematurity, and stillbirth. In March 2021, vaccination for at risk pregnant women was recommended in Switzerland, expanding this to all pregnant women in May 2021. Our aim was to assess the safety of mRNA COVID-19 vaccines in pregnancy.METHODS: This multicentre prospective cohort study describes early adverse events and perinatal outcomes in pregnant women who received at least one dose of mRNA vaccin...
Source: Herpes - June 2, 2022 Category: Infectious Diseases Authors: Guillaume Favre Emeline Maisonneuve L éo Pomar Ursula Winterfeld Charlotte Daire Bego ña Martinez de Tejada Dominique Delecraz Sonia Campelo Mirjam Moser Monya Todesco-Bernasconi Stefanie Sturm Irene H ösli C écile Monod Brigitte Frey Tirri Stylianos Source Type: research
